Impact of influenza infection on the short- and long-term health of patients with chronic obstructive pulmonary disease

References

• Centers for Disease Control and Prevention. Estimated flu-related illnesses, medical visits, hospsitalizations, and deaths in the United States–2019–2020 influenza season; 2021 [cited 2021 Nov 13]. Available from: https://www.cdc.gov/flu/about/burden/2019-2020.html
   Google Scholar
• Garten R, Blanton L, Elal AIA, et al. Update: Influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. Morb Mortal Wkly Rep. 2018;67(22):634–642.
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ballestros K, Echko M, et al. The state of US health, 1990–2016: burden of diseases, injuries, and risk factors among US states. JAMA. 2018;319(14):1444–1472.
   PubMed Web of Science ®Google Scholar
• Yu AP, Yang H, Wu EQ, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14(3):315–323.
   PubMedGoogle Scholar
• Dalal AA, Patel J, D'Souza A, et al. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm. 2015;21(7):575–583.
   PubMed Web of Science ®Google Scholar
• Patel JG, Coutinho AD, Lunacsek OE, et al. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 2018;13:2301–2311.
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245.
   PubMedGoogle Scholar
• Pasquale MK, Sun SX, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–764.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Skolnik N, Hansen GJ, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6.
   PubMed Web of Science ®Google Scholar
• Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15(3):536–542.
   PubMed Web of Science ®Google Scholar
• Zwaans WA, Mallia P, van Winden ME, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease–a systematic review. J Clin Virol. 2014;61(2):181–188.
   PubMed Web of Science ®Google Scholar
• Biancardi E, Fennell M, Rawlinson W, et al. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Intern Med J. 2016;46(10):1160–1165.
   PubMed Web of Science ®Google Scholar
• Herold S, Becker C, Ridge KM, et al. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J. 2015;45(5):1463–1478.
   PubMed Web of Science ®Google Scholar
• Betakova T, Kostrabova A, Lachova V, et al. Cytokines induced during influenza virus infection. Curr Pharm Des. 2017;23(18):2616–2622.
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Chughtai AA, Barnes M, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis. 2018;18(1):637.
   PubMedGoogle Scholar
• Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza a virus and bacterial coinfection in the United States. Crit Care Med. 2012;40(5):1487–1498.
   PubMed Web of Science ®Google Scholar
• Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–970.
   PubMed Web of Science ®Google Scholar
• Bekkat-Berkani R, Wilkinson T, Buchy P, et al. Seasonal influenza vaccination in patients with COPD: a systematic literature review. BMC Pulm Med. 2017;17(1):79.
   PubMed Web of Science ®Google Scholar
• Mallia P, Johnston SL. Influenza infection and COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(1):55–64.
   PubMedGoogle Scholar
• Mulpuru S, Li L, Ye L, et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest. 2019;155(1):69–78.
   PubMed Web of Science ®Google Scholar
• COPD Foundation. COPD and other respiratory conditions. ICD-9-CM and ICD-10-CM Reference Guide; 2021 [cited 2021 Nov 13]. Available from: https://www.copdfoundation.org/pdfs/ICD%20Reference%20Codes.pdf
   Google Scholar
• Stanford RH, Nag A, Mapel DW, et al. Validation of a new risk measure for chronic obstructive pulmonary disease exacerbation using health insurance claims data. Ann Am Thorac Soc. 2016;13(7):1067–1075.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Chronic obstructive pulmponary disease (COPD) FastStats; 2021 [cited 2021 Nov 13]. Available from: https://www.cdc.gov/nchs/fastats/copd.htm
   Google Scholar
• Troeger CE, Blacker BF, Khalil IA, et al. Morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the global burden of disease study 2017. Lancet Respir Med. 2019;7(1):69–89.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Donaldson GC. Natural history of successive COPD exacerbations. Thorax. 2012;67(11):935–936.
   PubMed Web of Science ®Google Scholar
• Keeler SP, Agapov EV, Hinojosa ME, et al. Influenza a virus infection causes chronic lung disease linked to sites of active viral RNA remnants. J Immunol. 2018;201(8):2354–2368.
   PubMed Web of Science ®Google Scholar
• Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124–1133.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–2107.
   PubMed Web of Science ®Google Scholar
• Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35(6):1209–1215.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019;23(1):258.
   PubMedGoogle Scholar
• Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;6:CD002733.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. People at higher risk of flu complications; 2021 [cited 2021 Nov 13]. Available from: https://www.cdc.gov/flu/about/disease/high_risk.htm
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–149.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J. 2008;15 (Suppl A):1A–8A.
   PubMed Web of Science ®Google Scholar
• Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza a H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395–404.
   PubMed Web of Science ®Google Scholar
• Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis. 2017;64(10):1328–1334.
   PubMed Web of Science ®Google Scholar
• Wallick C, Wu N, To T, et al. Treating influenza with antivirals is associated with a decreased burden of complicatons and health resource utilization in high risk patients. Presented at the Options X for the Control of Influenza Conference; 2019 August 28–September 1; Singapore; 2019. Abstract 11161, p. 35. Available from: https://isirvorg/site/images/conferences/Optionsx/Options%20X_Abstracts%20_Oral%20and%20Posterpdf
   Google Scholar
• Havers F, Flannery B, Clippard JR, et al. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013–2014 influenza season. Clin Infect Dis. 2015;60(11):1677–1680.
   PubMed Web of Science ®Google Scholar
• Lochner KA, Wynne MA, Wheatcroft GH, et al. Medicare claims versus beneficiary self-report for influenza vaccination surveillance. Am J Prev Med. 2015;48(4):384–391.
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Jembere N, Campitelli MA, et al. Using physician billing claims from the Ontario health insurance plan to determine individual influenza vaccination status: an updated validation study. CMAJ Open. 2016;4(3):E463–E470.
   PubMedGoogle Scholar